Sanofi

Latest stories

3h
FOX Business
Organovo Holdings, Inc. vs MannKind Corp.2015. Sales for the inhaled insulin in the last quarter totaled... well, there
Organovo Holdings, Inc. vs MannKind Corp.
FOX Business / Posted 3 hours ago
2015. Sales for the inhaled insulin in the last quarter totaled... well, there was no sales revenue reported by MannKind. Sanofiwas MannKind's marketing partner on the drug, and Sanofi threw in the towel on Afrezza in January after less than a... Read more
3h
FOX Business
Organovo Holdings, Inc. vs MannKind Corp.2015. Sales for the inhaled insulin in the last quarter totaled... well, there
Organovo Holdings, Inc. vs MannKind Corp.
FOX Business / Posted 3 hours ago
2015. Sales for the inhaled insulin in the last quarter totaled... well, there was no sales revenue reported by MannKind. Sanofiwas MannKind's marketing partner on the drug, and Sanofi threw in the towel on Afrezza in January after less than a... Read more
11h
FOX Business
What's Up With Mylan's EpiPen Pricing?which was announced on Monday. Campbell: This was probably the most-forecast a
What's Up With Mylan's EpiPen Pricing?
FOX Business / Posted 11 hours ago
which was announced on Monday. Campbell: This was probably the most-forecast acquisition in biotech history. You hadSanoficome out and make two different very public offers for the company. You had Medivation's board reject those very... Read more
11h
FOX Business
What's Up With Mylan's EpiPen Pricing?which was announced on Monday. Campbell: This was probably the most-forecast a
What's Up With Mylan's EpiPen Pricing?
FOX Business / Posted 11 hours ago
which was announced on Monday. Campbell: This was probably the most-forecast acquisition in biotech history. You hadSanoficome out and make two different very public offers for the company. You had Medivation's board reject those very... Read more
19h
The Toledo Blade
EpiPen maker offers generic versionEpiPen to the patient.” Analysts say Mylan has benefited from little competiti
EpiPen maker offers generic version
The Toledo Blade / Posted 19 hours ago
EpiPen to the patient.” Analysts say Mylan has benefited from little competition in the marketplace. One possible rival, Sanofi US, recalled its Auvi-Q epinephrine injector last fall because of accuracy problems, while Teva Pharmaceutical... Read more
288 related stories
1d
Bangor Daily News
Mylan to launch generic EpiPen at half the price of originalcould re-apply for approval and have its product on the market as soon as next
Mylan to launch generic EpiPen at half the price of original
Bangor Daily News / Posted yesterday
could re-apply for approval and have its product on the market as soon as next year, and win considerable market share. Sanofi SA pulled its own device from the market last year, also on concerns of inaccurate dosage. It returned rights to the... Read more
288 related stories
1d
Dallas Morning News
Drugmaker Mylan to offer cheaper generic for EpiPens, but Texas families remain concernedat other locations. One former competitor, Auvi-Q, went off the market last ye
Drugmaker Mylan to offer cheaper generic for EpiPens, but Texas families remain concerned
Dallas Morning News / Posted yesterday
at other locations. One former competitor, Auvi-Q, went off the market last year after a recall from French drug maker Sanofi. Concerns that the device was delivering inaccurate doses alarmed parents who had been relying on it in case of an... Read more
288 related stories
1d
FOX Business
Here's How MannKind Corp. Could Stage a Miraculous Comebacka jaw-droppingdeficit of $2.9 billion since inception,and is still losing aroun
Here's How MannKind Corp. Could Stage a Miraculous Comeback
FOX Business / Posted yesterday
a jaw-droppingdeficit of $2.9 billion since inception,and is still losing around $30 million per quarter. Most importantly, Sanofi's (NYSE: SNY)decision to hand the commercial rights back for Afrezza is a major blow to the drug's commercial... Read more
1d
FOX Business
Here's How MannKind Corp. Could Stage a Miraculous Comebacka jaw-droppingdeficit of $2.9 billion since inception,and is still losing aroun
Here's How MannKind Corp. Could Stage a Miraculous Comeback
FOX Business / Posted yesterday
a jaw-droppingdeficit of $2.9 billion since inception,and is still losing around $30 million per quarter. Most importantly, Sanofi's (NYSE: SNY)decision to hand the commercial rights back for Afrezza is a major blow to the drug's commercial... Read more
1d
Reuters
Mylan to launch generic EpiPen at half the price of original(ADMP.O) rival treatment in June and Teva Pharmaceutical Industries Ltd's (TEVA
Mylan to launch generic EpiPen at half the price of original
Reuters / Posted yesterday
(ADMP.O) rival treatment in June and Teva Pharmaceutical Industries Ltd's (TEVA.TA) generic version earlier this year. Sanofi SA (SASY.PA) has pulled its device from the market last year on concerns of inaccurate dosage. Leerink Partners said... Read more
288 related stories
1d
Newsmax
Mylan to Sell Generic EpiPen for Half the Price of Originalor insects such as bees. U.S. health regulators rejected Adamis Pharmaceutical
Mylan to Sell Generic EpiPen for Half the Price of Original
Newsmax / Posted yesterday
or insects such as bees. U.S. health regulators rejected Adamis Pharmaceuticals Corp's rival treatment to EpiPen in June. Sanofi has pulled its device from the market and Teva Pharmaceutical Industries Ltd was forced to delay the launch of its... Read more
17 related stories
1d
Newsmax
Mylan to Launch Generic EpiPen After Outcry Over Price Gougingor insects such as bees. U.S. health regulators rejected Adamis Pharmaceutical
Mylan to Launch Generic EpiPen After Outcry Over Price Gouging
Newsmax / Posted yesterday
or insects such as bees. U.S. health regulators rejected Adamis Pharmaceuticals Corp's rival treatment to EpiPen in June. Sanofi has pulled its device from the market and Teva Pharmaceutical Industries Ltd was forced to delay the launch of its... Read more
17 related stories
1d
Market Watch
Sanofi, Regeneron's cholesterol drug meets targetPARIS--Sanofi and U.S. drugmaker Regeneron Pharmaceuticals, Inc. Monday said th
Sanofi, Regeneron's cholesterol drug meets target
Market Watch / Posted yesterday
PARIS--Sanofi and U.S. drugmaker Regeneron Pharmaceuticals, Inc. Monday said that their jointly developed cholesterol drug Praluent met targets in a clinical trial, reducing cholesterol in people with a hereditary high-cholesterol disorder and... Read more
2d
Orlando Sentinel
Illinois parents feel EpiPen price pain as school year startsfull price for the product. Critics say there are other factors at play, namel
Illinois parents feel EpiPen price pain as school year starts
Orlando Sentinel / Posted 2 days ago
full price for the product. Critics say there are other factors at play, namely a lack of major competing products. Sanofi US made a similar device called Auvi-Q, but it recalled the product last year because of potentially inaccurate dosage... Read more
607 related stories
2d
The Express-Times
Stick it: Flu clinics reject nasal vaccine for 2016-17 (VIDEO)potentially deadly respiratory illness is there is plenty of injectable vaccine
Stick it: Flu clinics reject nasal vaccine for 2016-17 (VIDEO)
The Express-Times / Posted 2 days ago
potentially deadly respiratory illness is there is plenty of injectable vaccine manufactured by Monroe County-based Sanofi Pasteur. The Swiftwater, Pennsylvania, company is the world's largest manufacturer of seasonal influenza vaccines and... Read more
3d
FOX Business
These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a YearReading Below Image source: Amgen. Clinical trial results for both approved P
These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year
FOX Business / Posted 3 days ago
Reading Below Image source: Amgen. Clinical trial results for both approved PCSK-9 inhibitors -- Amgen's Repatha, and Sanofi(NYSE: SNY) and Regeneron Pharmaceuticals' (NASDAQ: REGN) Praluent -- have thus far dazzled Wall Street. Repatha gained... Read more
4d
Daily Mail
Why ARE EpiPens getting more expensive?Teva Pharmaceuticals, failed to obtain regulatory approval, delaying their entr
Why ARE EpiPens getting more expensive?
Daily Mail / Posted 4 days ago
Teva Pharmaceuticals, failed to obtain regulatory approval, delaying their entry into the market. Another competitor, Sanofi, recalled its competing epinephrine delivery device because it may be delivering in incorrect dosage. That leaves... Read more
607 related stories
4d
Chicago Tribune
Illinois parents feel EpiPen price pain as school year startsfull price for the product. Critics say there are other factors at play, namel
Illinois parents feel EpiPen price pain as school year starts
Chicago Tribune / Posted 4 days ago
full price for the product. Critics say there are other factors at play, namely a lack of major competing products. Sanofi US made a similar device called Auvi-Q, but it recalled the product last year because of potentially inaccurate dosage... Read more
607 related stories
4d
MLive.com
Ways people cut corners on expensive EpiPens, and why they shouldn'twholesalers or distributors and many pharmacies may not be able to obtain them
Ways people cut corners on expensive EpiPens, and why they shouldn't
MLive.com / Posted 4 days ago
wholesalers or distributors and many pharmacies may not be able to obtain them because they are not widely distributed. Sanofi US voluntarily recalled all Auvi Q® epinephrine injections currently on the market, including both the 0.15 mg and 0.3... Read more
4d
Market Watch
What it’s like to have life-threatening allergies and be unable to afford the EpiPenbeen price gouging on the life-saving device which has a more than 90% market s
What it’s like to have life-threatening allergies and be unable to afford the EpiPen
Market Watch / Posted 4 days ago
been price gouging on the life-saving device which has a more than 90% market share. EpiPen’s rival Auvi-Q, produced by Sanofi US, was recalled in October 2015 after the FDA determined the auto-injector could deliver an incorrect dose. Earlier... Read more
607 related stories
4d
5KSDK St. Louis
The real reason the EpiPen and other off-patents are so expensiveTeva Pharmaceuticals, failed to obtain regulatory approval, delaying their entr
The real reason the EpiPen and other off-patents are so expensive
5KSDK St. Louis / Posted 4 days ago
Teva Pharmaceuticals, failed to obtain regulatory approval, delaying their entry into the market Another competitor, Sanofi, recalled its competing epinephrine delivery device because it may be delivering in incorrect dosage. That leaves... Read more
7 related stories
4d
Profit Confidential
Best Biotech Stocks: This $15 Biotech Stock is About to Go Verticalterms of market action. Consider that there is always the chance that one biot
Best Biotech Stocks: This $15 Biotech Stock is About to Go Vertical
Profit Confidential / Posted 4 days ago
terms of market action. Consider that there is always the chance that one biotech could become the Pfizer Inc. (NYSE:PFE), Sanofi SA (NYSE:SNY), or Merck & Co., Inc. (NYSE:MRK) of tomorrow. A top biotech stock in the U.S. market can double or... Read more
4d
The Scranton Times-Tribune
Price hike for Epi-pens shocks local residentsspike to a variety of factors, including the fact Mylan gained a virtual monopo
Price hike for Epi-pens shocks local residents
The Scranton Times-Tribune / Posted 4 days ago
spike to a variety of factors, including the fact Mylan gained a virtual monopoly in the market after its chief competitor, Sanofi, recalled its epinephrine auto-injector in October over concerns it was not providing the correct dosage. “It’s... Read more
607 related stories
4d
The Toledo Blade
EpiPen price draws rage, questionsEpiPen has captured about 94 percent of the market for the drug. Mylan benefit
EpiPen price draws rage, questions
The Toledo Blade / Posted 4 days ago
EpiPen has captured about 94 percent of the market for the drug. Mylan benefited from two developments: the decision by Sanofi US last fall to take its Auvi-Q epinephrine injector off the market because of problems with the accuracy of the... Read more
10 related stories
4d
dna
Dengue vaccine eluded science for decades, here's why(ADE) of the infection, this is why the second bout of dengue is always more da
Dengue vaccine eluded science for decades, here's why
dna / Posted 4 days ago
(ADE) of the infection, this is why the second bout of dengue is always more dangerous than the first. It is also why Sanofi Pasteur's vaccine Dengvaxia, released last year as the first dengue vaccine, is limited in scope. If given to someone... Read more
4d
The Chattanoogan
Abused By An EpiPen$18.9 million – a 671 percent increase – because (wink! wink!) sales are good.
Abused By An EpiPen
The Chattanoogan / Posted 4 days ago
$18.9 million – a 671 percent increase – because (wink! wink!) sales are good. You see, the only competition Mylan had was Sanofi’s Auvi-Q. But in October last year when it was discovered the Sanofi device had an inaccurate dose delivery, all... Read more
607 related stories
5d
Dallas Morning News
Drug maker Mylan tries to satisfy critics as EpiPen price hikes draw scorngained more than about 10 percent market share before it went off the market la
Drug maker Mylan tries to satisfy critics as EpiPen price hikes draw scorn
Dallas Morning News / Posted 5 days ago
gained more than about 10 percent market share before it went off the market last year after a recall by French drugmaker Sanofi. Nancy Lyons, a teacher who runs Austin Families with Food Allergies, a support group, had used Auvi-Q for several... Read more
607 related stories
5d
WBTV Charlotte
EpiPen prices anger Charlotte families that need them to keep kids safehuge raises while raising the drug’s price. Mylan has a virtual monopoly on Ep
EpiPen prices anger Charlotte families that need them to keep kids safe
WBTV Charlotte / Posted 5 days ago
huge raises while raising the drug’s price. Mylan has a virtual monopoly on EpiPens since last year, when drug maker Sanofi voluntarily recalled a competing device, Auvi-Q, because it may not have been delivering the correct dose. A generic... Read more
607 related stories
5d
FOX Business
Why Mylan's EpiPen Is Sparking Epi-Rageauto-injectors, even those manufactured by competitors. Until last year, Mylan
Why Mylan's EpiPen Is Sparking Epi-Rage
FOX Business / Posted 5 days ago
auto-injectors, even those manufactured by competitors. Until last year, Mylan's EpiPen was battling for market share with Sanofi'sAuvi-Q, an auto-injector that received the FDA's green light in 2012. After Auvi-Q's launch, the EpiPen remained the... Read more
607 related stories
5d
FOX Business
Why Mylan's EpiPen Is Sparking Epi-Rageauto-injectors, even those manufactured by competitors. Until last year, Mylan
Why Mylan's EpiPen Is Sparking Epi-Rage
FOX Business / Posted 5 days ago
auto-injectors, even those manufactured by competitors. Until last year, Mylan's EpiPen was battling for market share with Sanofi'sAuvi-Q, an auto-injector that received the FDA's green light in 2012. After Auvi-Q's launch, the EpiPen remained the... Read more
607 related stories
5d
Fortune
Mylan Halves EpiPen Price After Being Savaged by Clintongenerates over $1 billion a year in revenue for the company. Mylan has had a n
Mylan Halves EpiPen Price After Being Savaged by Clinton
Fortune / Posted 5 days ago
generates over $1 billion a year in revenue for the company. Mylan has had a near-monopoly in the space in the U.S. since Sanofi SA snynf withdrew a competing product last year. The FDA has also refused to register a generic alternative from... Read more
607 related stories
5d
Raw Story
The real reason the EpiPen and other off-patents are so expensiveTeva Pharmaceuticals, failed to obtain regulatory approval, delaying their entr
The real reason the EpiPen and other off-patents are so expensive
Raw Story / Posted 5 days ago
Teva Pharmaceuticals, failed to obtain regulatory approval, delaying their entry into the market Another competitor, Sanofi, recalled its competing epinephrine delivery device because it may be delivering in incorrect dosage. That leaves... Read more
7 related stories
5d
FOX News
Over 14,000 women took Sanofi epilepsy drug despite fetus risk: ministryPARIS – More than 14,000 pregnant women in France took Sanofi's anti-epilepsy d
Over 14,000 women took Sanofi epilepsy drug despite fetus risk: ministry
FOX News / Posted 5 days ago
PARIS – More than 14,000 pregnant women in France took Sanofi's anti-epilepsy drug Depakine between 2007 and 2014 even though the risk of fetus malformation was known, according to a study released by France on Wednesday. Health Minister Marisol... Read more
5d
CBS News
Soaring insulin prices have diabetics feeling the painall, isn’t a new medication. It was developed almost a century ago, but just th
Soaring insulin prices have diabetics feeling the pain
CBS News / Posted 5 days ago
all, isn’t a new medication. It was developed almost a century ago, but just three pharmaceutical companies -- Eli Lilly, Sanofi (SNY​) and Novo Nordisk (NVO​) -- own the patents to producing it. All three have hiked their prices from 2010 to... Read more
5d
Fortune
Here's Who Mylan CEO Is Blaming for EpiPen Sticker Shockcontracts with pharmacies and distributors this year that kept the EpiPen compe
Here's Who Mylan CEO Is Blaming for EpiPen Sticker Shock
Fortune / Posted 5 days ago
contracts with pharmacies and distributors this year that kept the EpiPen competitively priced with is biggest competitor, Sanofi’s Auvi-Q. But now that the Sanofi snynf drug is no longer on the market—the company recalled its entire supply last... Read more
607 related stories
5d
WWLP Springfield
Snapshot reveals growth in healthy Bay State biopharma sectorand 63,026 total biopharma industry jobs. The average salary was $147,432. The
Snapshot reveals growth in healthy Bay State biopharma sector
WWLP Springfield / Posted 5 days ago
and 63,026 total biopharma industry jobs. The average salary was $147,432. The state’s largest biopharma employers are Sanofi Genzyme, Biogen, Shire, Novartis, Takeda, Pfizer, Parexel International, Quest Diagnostics, Vertex, Charles River... Read more
6d
San Antonio Express-News
Pfizer spent $14 billion on a company with just one approved drug — here's why that's a game changer (MDVN, PFE)deal. "We believe the additional premium of 21% over the current Medivation st
Pfizer spent $14 billion on a company with just one approved drug — here's why that's a game changer (MDVN, PFE)
San Antonio Express-News / Posted 6 days ago
deal. "We believe the additional premium of 21% over the current Medivation stock price — which was already trading at the Sanofi takeout bid premium — does clearly highlight the willingness of companies to pay substantial prices given unmet need... Read more
117 related stories
6d
FOX Business
Dear Pfizer, Stop Overpaying for Acquisitions!MDVN) for $14 billion, or $81.50 per share in cash. Medivation has been on the
Dear Pfizer, Stop Overpaying for Acquisitions!
FOX Business / Posted 6 days ago
MDVN) for $14 billion, or $81.50 per share in cash. Medivation has been on the auction block for months, with Sanofi(NYSE: SNY) seeming as if it'd be the most likely suitor. Sanofi had made multiple offers for Medivation that... Read more
117 related stories
6d
FOX Business
Dear Pfizer, Stop Overpaying for Acquisitions!MDVN) for $14 billion, or $81.50 per share in cash. Medivation has been on the
Dear Pfizer, Stop Overpaying for Acquisitions!
FOX Business / Posted 6 days ago
MDVN) for $14 billion, or $81.50 per share in cash. Medivation has been on the auction block for months, with Sanofi(NYSE: SNY) seeming as if it'd be the most likely suitor. Sanofi had made multiple offers for Medivation that... Read more
117 related stories
6d
Market Watch
Congress joins fight over rising cost of EpiPens as Shkreli defendsthat EpiPen’s price increase was happening as the company gained market share,
Congress joins fight over rising cost of EpiPens as Shkreli defends
Market Watch / Posted 6 days ago
that EpiPen’s price increase was happening as the company gained market share, due to similar products, the Auvi-Q from Sanofi US, recalled in the fall of 2015 and Teva failing to gain approval for its generic drug earlier this year. “Not only... Read more
607 related stories
6d
Newsmax
Price for Anti-Allergy EpiPens Jumps to Over $500rights to EpiPen from Merck in 2007. It had faced some competition from a produ
Price for Anti-Allergy EpiPens Jumps to Over $500
Newsmax / Posted 6 days ago
rights to EpiPen from Merck in 2007. It had faced some competition from a product marketed by French pharmaceutical company Sanofi, but that was pulled from the market last year amid quality problems, boosting EpiPen's market from the 85 percent it... Read more
607 related stories
6d
Business Wire
Project Data Sphere® Appoints David Handelsman Vice President of DevelopmentEMD Serono, Janssen, Eli Lilly, Memorial Sloan Kettering Cancer Center, Millenn
Project Data Sphere® Appoints David Handelsman Vice President of Development
Business Wire / Posted 6 days ago
EMD Serono, Janssen, Eli Lilly, Memorial Sloan Kettering Cancer Center, Millennium-the Takeda Oncology Company, Pfizer, Sanofi, Synta and The Alliance for Clinical Trials in Oncology, one of five US research groups of the National Cancer... Read more
6d
FOX Business
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversiontrying to work its way through the FDA. I’ve been in this for 11 years. We’ve s
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversion
FOX Business / Posted 6 days ago
trying to work its way through the FDA. I’ve been in this for 11 years. We’ve seen Twin-ject come and go, Auvi-Q (by Sanofi US) come and go.. Auvi-Q was recalled because of 26 unconfirmed reports. There needs to be an investigation into how... Read more
72 related stories
6d
FOX Business
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversiontrying to work its way through the FDA. I’ve been in this for 11 years. We’ve s
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversion
FOX Business / Posted 6 days ago
trying to work its way through the FDA. I’ve been in this for 11 years. We’ve seen Twin-ject come and go, Auvi-Q (by Sanofi US) come and go.. Auvi-Q was recalled because of 26 unconfirmed reports. There needs to be an investigation into how... Read more
72 related stories
6d
The Hill
Competition is the cure for EpiPen’s price hikecompetitors? A quick look at the market would find it’s not for lack of trying:
Competition is the cure for EpiPen’s price hike
The Hill / Posted 6 days ago
competitors? A quick look at the market would find it’s not for lack of trying: Auvi-Q, a “talking” autoinjector made by Sanofi, was recalled after patients reported receiving inaccurate doses of epinephrine, the drug injected through... Read more
607 related stories
6d
The Seattle Times
As EpiPen prices rocket up, lawmakers demand answerseven more money.Competitors falter In 2012, the competing devices Adrenaclick
As EpiPen prices rocket up, lawmakers demand answers
The Seattle Times / Posted 6 days ago
even more money.Competitors falter In 2012, the competing devices Adrenaclick and Twinject were discontinued. In 2013, Sanofi began to sell Auvi-Q devices, which had audio instructions. Unfortunately, they were found to give potentially... Read more
607 related stories
6d
International Business Times
Congress members call for investigation into Mylan for 'outrageous' price hike of the EpiPenthe medication itself is not expensive, Mylan has near monopoly over the medica
Congress members call for investigation into Mylan for 'outrageous' price hike of the EpiPen
International Business Times / Posted 6 days ago
the medication itself is not expensive, Mylan has near monopoly over the medication's injectors. PBS NewsHour reported that Sanofi was forced to recall its own injector due to dosing issues, while Teva Pharmaceuticals was unable to win regulatory... Read more
14 related stories
7d
Los Angeles Times
Another reason to hate Mylan, which jacked up the price of life-saving EpiPens: It's a tax dodgerand development costs. Instead, it’s simply profiteering from market dynamics:
Another reason to hate Mylan, which jacked up the price of life-saving EpiPens: It's a tax dodger
Los Angeles Times / Posted 7 days ago
and development costs. Instead, it’s simply profiteering from market dynamics: Its main competitor, a product made by Sanofi, was taken off the market last year because of manufacturing defects. Another potential rival, from the generics... Read more
72 related stories
7d
Roll Call
Obama Administration Announces Added $60 Million to Fight ZikaDefense is also working on a vaccine for the virus. It announced earlier this y
Obama Administration Announces Added $60 Million to Fight Zika
Roll Call / Posted 7 days ago
Defense is also working on a vaccine for the virus. It announced earlier this year an agreement with pharmaceutical giant Sanofi S.A. to pursue advanced development of the treatment. The treatment is currently in early human trials, which are... Read more
7d
Channel NewsAsia
Price rise for anti-allergy EpiPen sparks furore in USrights to EpiPen from Merck in 2007. It had faced some competition from a produ
Price rise for anti-allergy EpiPen sparks furore in US
Channel NewsAsia / Posted 7 days ago
rights to EpiPen from Merck in 2007. It had faced some competition from a product marketed by French pharmaceutical company Sanofi, but that was pulled from the market last year amid quality problems, boosting EpiPen's market from the 85 percent it... Read more
607 related stories
More

People in this news